NTEC Key Statistics, Chart & Performance
The current stock price of NTEC is 9.63 null. In the past month the price decreased by -27.7%. In the past year, price decreased by -71.32%.
NTEC Technical Analysis
NTEC Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NTEC. NTEC has a bad profitability rating. Also its financial health evaluation is rather negative.
NTEC Financial Highlights
Over the last trailing twelve months NTEC reported a non-GAAP Earnings per Share(EPS) of -3.44. The EPS increased by 80.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -83.12% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
NTEC Forecast & Estimates
3 analysts have analysed NTEC and the average price target is 53.04 null. This implies a price increase of 450.78% is expected in the next year compared to the current price of 9.63.
NTEC Ownership
NTEC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About NTEC
Company Profile
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. The company is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The firm is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
Company Info
Intec Parent Inc
12 Hartom Street, Har Hotzvim
JERUSALEM 777512 IL
CEO: Jeffrey A. Meckler
Employees: 70
Phone: 97225864657.0
Intec Parent Inc / NTEC FAQ
What does NTEC do?
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. The company is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs. The firm is focusing on the clinical development program for the Phase III clinical study of the Accordion Pill Carbidopa Levodopa (AP-CDLD), for the treatment of advanced stages Parkinson’s disease patients. Its pipeline also comprises The Accordion Pill-Zaleplon, a drug for sleep onset, which is in Phase II clinical program. Furthermore under research is Accordion Pill-Undisclosed Drug for the prevention and treatment of small bowel non-steroidal anti-inflammatory drug (NSAID) induced ulcers.
What is the stock price of Intec Parent Inc today?
The current stock price of NTEC is 9.63 null. The price decreased by -12.48% in the last trading session.
What is the dividend status of Intec Parent Inc?
NTEC does not pay a dividend.
How is the ChartMill rating for Intec Parent Inc?
NTEC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for NTEC stock?
Intec Parent Inc (NTEC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.44).
What is the employee count for NTEC stock?
Intec Parent Inc (NTEC) currently has 70 employees.